Quantitative reverse transcription PCR (RT-PCR) was used to measure gene expressions (relative mRNA levels) of p16 and the alternate transcript p16b in esophageal and gastric tumors. p16 gene expression was undetectable in 13 of 25 esophageal squamous cell carcinomas. In 11 of these tumors, p16b was simultaneously missing whereas two of the p16-de®cient tumors still expressed p16b. Among 34 esophageal adenocarcinomas and 11 gastric adenocarcinomas, only one tumor lacked p16 expression and all tumors expressed p16b. p16 sequences were not detectable by PCR in genomic DNA from tumors lacking both p16 and p16b mRNA, suggesting that the simultaneous loss of both gene expressions resulted from homozygous genomic deletion of the p16 gene. However, DNA from tumors that lacked p16 mRNA but expressed p16b did contain the p16 gene, consistent with loss of p16 expression in these tumors by transcriptional suppression. No point mutations in p16 cDNA were detected among 12 that were sequenced, but one p16 cDNA from a squamous cell carcinoma had a 19-base deletion, possibly indicating a splice-site mutation. Among those tumors that expressed p16 mRNA, the gene expression values of both p16 and p16b varied over a wide range. In some cases, p16 expression was detectable but low, suggesting that down-regulation of p16 expression may be used in some cases to achieve the funtional equivalent of gene deletion or transcriptional silencing. These results demonstrate that p16 expression patterns dier based on tumor histology and origin. Homozygous deletion of p16 appears to be common in esophageal squamous cell carcinomas but in adenocarcinomas, both gene deletion and transcriptional silencing of p16 were infrequent.
Introduction

The p16
INK4a/MTS1/CDKN2 gene, which codes for the cyclindependent kinase inhibitory protein p16, has been found to be altered in human cancers at a frequency rivaling that of the p53 gene (Kamb et al., 1994) . Three distinct types of p16 alterations have been identi®ed in tumor cells: (1) sequence changes in genomic DNA such as point mutations or small deletions (reviewed in Pollock et al., 1996) ; (2) homozygous deletion (HD) of long segments of DNA that include p16 (Stone et al., 1995a) ; and (3) transcriptional suppression of p16 by methylation of the promoter region and exon 1 Otterson et al., 1995) . Studies showing that restoration of p16 expression in cancer cells causes dramatic growth suppression (Jin et al., 1995) and that p16 knockout mice develop spontaneous tumors at an early age (Serrano et al., 1996) provide compelling evidence that p16 functions as a tumor suppressor. More recently, a novel transcript was discovered that shares exons 2 and 3 with p16 but has a dierent exon 1 about 15 kb upstream of exon 1 of p16 Quelle et al., 1995) . Whether this protein, called p16b, functions as a tumor suppressor gene is not known and whether its regulation is in any way connected to that of p16 is not ®rmly established.
Because several recent studies have indicated an association between altered p16 and more aggessive and drug-resistant tumors (Reed et al., 1995; Bartsch et al., 1996; Heyman et al., 1996; Kratzke et al., 1996) , we were interested in characterizing p16 status in esophageal tumors and other tumors of the upper gastrointestinal tract in order eventually to determine the clinical relevance of these data with regard to tumor response, recurrence and survival of patients with these cancers. Although a number of previous studies have addressed p16 status in esophageal cancer, the results of these studies are not in accord as to the type and the frequency of p16 alterations. One early study reported a high p16 mutation rate of 52% (Mori et al., 1994) but subsequent studies found much lower mutation frequencies (Zhou et al., 1994; Igaki et al., 1995; Maesawa et al., 1996) . Although esophageal squamous cell carcinoma (ESCC) cell lines were found to have a high frequency of HD of the p16 gene (Liu et al., 1995; Igaki et al., 1994 Igaki et al., , 1995 reported ®nding no HD of p16 among 25 primary ESCC tumors. However, HD of p16 were found in metastatic tissue from late stage ESCC tumors (Maesawa et al., 1996) . The reported lack of HD among primary ESCC tumors was surprising to us considering the high frequency (67%) of HD of p16 recently found in head-and-neck squamous cell carcinoma (HNSCC) (Reed et al., 1996) , a tumor with etiology similar to ESCC. In addition to these alterations in gene sequence, Maesawa et al. (1996) also reported transcriptional silencing of p16 expression by methylation at a frequency of about 20% in ESCC.
Because detection of HD in genomic DNA can be compromised by the presence of non-neoplastic cells in the tissue specimen and because DNA-based analyses are not diagnostic for the amount of gene expression, several recent studies on p16 status in tumors utilized expression analyses involving immunohistochemistry with p16-speci®c antibodies to identify tumors that do and do not contain p16 (Reed et al., 1996; Geradts et al., 1995; Liggett et al., 1996; Kratzke et al., 1995) . With this methodology, it was possible to correct earlier conclusions about the lack of HD of p16 in HNSCC (Reed et al., 1995) . Another expression assay, which has been used relatively little for studying p16 gene expression, is quantitative RT-PCR. From previous work, we had found that RT-PCR-based methodology is capable of quantitating the relative amount of a speci®c mRNA (as its cDNA) with good precision and reproducibility in biopsy-sized tumor specimens (Lenz et al., , 1996 . With RT-PCR, it should be possible to identify cases of lack of gene expression, overexpression, as well as lower expression levels that might be counted as loss of expression with less sensitive assays. In the present study, we applied RT-PCR to determine the quantitative range of p16 expression in esophageal and gastric tumors. Furthermore, because multiple gene expressions can be quantitated from the same cDNA solution with RT-PCR, we also examined the relationship between p16 and p16b expressions in the same tumor sample.
Using the quantitative RT-PCR methodology, we found that loss of both p16 and p16b expression occurred with a high frequency in primary ESCC, most likely as a result of HD, and that loss of p16b expression never occurred as an exclusive event but only in concert with a loss of p16 and only in ESCC. However, in EAC and gastric adenocarcinomas (GAC) the loss of p16 expression is a comparatively rare event.
Results
Quantitative RT-PCR analysis of p16 and p16b gene expressions Figure 1 shows representative curves used for quantitation of relative p16 mRNA content in two esophageal tumors, one representing a tumor with substantial p16 expression (L364) and the other representing one with no p16 expression (K8). Both of these tumors expressed p16b. The primers that we developed for PCR ampli®cation of p16 and p16b cDNA gave a linear ampli®cation over more than a 2 log range of cDNA concentration. Gene expression values were reported only if the PCR generated a set of distinct bands with intensities that were linear with the concentration of cDNA. The slopes of the lines were obtained from at least three data points, so that each reported gene expression value represents the average of a minimum of three and often four separate PCR reactions within the linear ampli®cation range. When the initially chosen cDNA concentrations for a particular determination gave PCR products were clearly outside of the proportional linearity region, the determination was repeated with adjusted cDNA concentrations until the data points were in the linear range and the correlation coecient for linearity for a set of at least three consecutive serial dilutions plus the zero point was greater than 0.90. When gene expression values are obtained within the proper linear amplification ranges, repeat determinations are generally within +10% of each other.
p16 and p16b expression patterns in ESCC
No p16 PCR products were detectable in 13/25 (52%) ESCC specimens ( Table 1 ). The remaining 12 tumors had measurable p16 expression, but one of the mRNA (L241) was abnormal, containing a deletion in exon 3. The 11 tumors with apparently normal mRNA had a mean p16/b-actin ratio of 162, and a range of variation of p16 mRNA levels of 180-fold. PCR products from p16b were undetectable in nine of the 13 tumors lacking p16 expression (70%). In no case was there exclusive absence of p16b expression without the simultaneous loss of p16 expression. Among the p16b expressors, the mean p16b/b-actin ratio was 336, with a 34-fold dierence between the highest and lowest expressor.
p16 and p16b expression patterns in EAC Gene expression values represent the slopes of plots as shown in Figure 1 , which include data points from at least three separate PCR reactions plus the zero point, with a linearity correlation coecient of 40.90. *The mRNA was expressed but bases 386 ± 405 were deleted L50  L57  L59  L88  L322  L364  L462  MSK05  MSK15  MSK33  MSK37  1M20  4M9  12M39  16M0  21M11  22M2  23M10  26M25  27M40   1500  22  40  23  0  86  43  21  314  99  54  251  25  90  79  210  56  138  19  85  47   487  269  353  964  1331  104  242  1093  132  89  54  325  390  125  120  161  184  385  34  142  291 Gene expression values represent the slopes of plots as shown in Figure 1 , which include data points from at least three separate PCR reactions plus the zero point, with a linearity correlation coecient of 40.90
p16 and p16b alterations in esophageal tumors K Hayashi et al observed among the GAC (Table 3) , but p16 in tumor 8M32 was so low that it could represent a possible loss of p16 expression in the tumor with some normal tissue in®ltration of the specimen. The mean p16/b-actin ratio was 48, with a range of variation of 42, but if tumor 8M32 is excluded, the range of variation among the p16 expression values was only 11-fold. The mean p16b/b-actin ratio was 151 with a range of variation of 86-fold but only 19-fold if the overexpressing tumor 2M21 is not included.
Analysis of genomic DNA for p16 deletions
Because of the exon sharing between p16 and p16b, we hypothesized that the most likely mechanism to account for a simultaneous absence of p16 and p16b expressions was HD deletion of the p16 gene. Because sucient DNA could not be obtained from extracts of the biopsy material for demonstration of HD by Southern blotting, we examined genomic DNA for the presence of p16 sequences by PCR analysis using primers designed to amplify a portion of exon 2, with the 5'-primer complementary to an intron¯anking this exon. As shown in Figure 2 , PCR of genomic DNA from four tumors lacking both gene expressions (K3, K5, K9 and K20) failed to generate any p16 gene fragment. PCR ampli®cation of the DNA of K8 and K21, which are tumors that expressed p16b but not p16, generated the expected fragment of the p16 gene, providing con®rmatory evidence that the p16(7)p16b(+) expression phenotype represents transcriptional suppression of p16. For positive controls, PCR was performed on genomic DNA from four tumors expressing both p16 and p16b (K6, K10, K13 and K15). All of these tumors generated a PCRampli®ed p16 gene fragment.
p16 and p16b expression in normal esophageal tissues
Four specimens of esophageal normal tissue were available for analysis (Table 4 ). The mean p16/b-actin ratio was 5.5 with a fourfold range of variation. The mean p16b/b-actin ratio was 49 with a 4.5-fold range of variation.
Sequence analysis of p16 cDNA
The cDNA from specimens L21, L24, L241, L324, L3, L50, L57, L59, L88, L322, L364, L462 were sequenced. All of these tumors except for L88 contained measurable amounts of p16 cDNA. In the case of L88, only exons 2 and 3 were sequenced. No point mutations of p16 were detected in cDNA of any of these tumors. However, in the p16 cDNA of tumor L241, bases 386-405 of the coding region were deleted.
Figure 2 PCR analysis of genomic DNA for the presence of p16 sequences. To ensure speci®city for ampli®cation of genomic DNA, the 5'-primer was designed to bind to the intron adjacent to exon 2 of the p16 gene 3M24  5M29  6M1  7M28  8M32  9M30  10M35  11M36  14M7  15M14  17M13  20M12  24M17  28M27   71  13  31  38  61  3  58  18  41  80  70  11  50  125  31   948  11  15  173  40  19  60  170  130  145  156  106  206  120  30 Gene expression values represent the slopes of plots as shown in Figure 1 , which include data points from at least three separate PCR reactions plus the zero point, with a linearity correlation coecient of 40.90 Gene expression values represent the slopes of plots as shown in Figure 1 , which include data points from at least three separate PCR reactions plus the zero point, with linearity correlation coecient of 40.90
p16 and p16b alterations in esophageal tumors K Hayashi et al
Discussion
Using quantitative RT-PCR to measure relative mRNA content of tumor tissue specimens, we found that p16 expression varied widely among tumors of the esophagus and stomach, ranging from zero to very high expression. A striking dierence was noted in the incidence of p16 expression loss based on tumor histology: loss of p16 expression was found in only one tumor among the adenocarcinomas, whereas about half of the ESCC had complete lack of p16 expression. Moreover, in the majority of cases of p16 expression loss in the ESCC, p16b expression was also deleted. Previous studies have identi®ed two speci®c mechanisms which could lead to lack of a p16 transcript: HD of the p16 gene and transcriptional silencing by methylation. Although methylation of both p16 and p16b is conceivable, the occurrence of HD targeted at loss of the p16 gene is probably a much more likely mechanism for the simultaneous loss of p16 and p16b expressions because of the exon sharing between p16 and p16b. Analogously, the simultaneous lack of expression of the p16 and p15 (CDKN4b) genes, which do not share exons but are located near each other on chromosome 9p21, corresponded perfectly to HD of p16 in ESCC cell lines (Zhou et al., 1994) . Consistent with HD of the p16 gene, PCR analysis of genomic DNA from several of the p16 (7)p16b (7) phenotype tumors showed the absence of at least the p16 gene segments de®ned by the PCR primers. Expression of p16b precludes HD of the gene, so the p167)/p16b(+) expression phenotype probably represents transcriptional silencing of p16, either by methylation or by some other mechanism for suppressing p16 gene expression, although selective deletion of p16 exon 1 is also a possibility. As expected, p16 sequences from exons 2 and 3 were detected by PCR in the genomic DNA of several p16(7)/p16b(+) tumors. The apparent HD frequency of about 50% indicated by the double loss of p16 and p16b expressions in our ESCC specimens contradicts two previous studies, both of which failed to ®nd HD in primary esophageal SCC by analysing genomic DNA (Igaki et al., 1995; Maesawa et al., 1996) . The frequency of HD in ESCC indicated by our data, however, would match the HD frequencies reported for cultured ESCC cells (Igaki et al., 1994) and thus resolve the in vitro ± in vivo discrepancy of p16 status in esophageal cancer. Supporting our present conclusions about high HD frequency in ESCC is a remarkable parallelism with studies of p16 alterations in HNSCC. Zhang et al. (1994) in an early study found a high frequency (44%) of HD in HNSCC cell lines but did not detect a single HD in 68 primary HNSCC, while found the p16 gene to be homozygously deleted in only one of 19 cases of HNSCC. However, subsequently Reed et al. (1996) used IHC analysis to show that 83% of primary HNSCC tumors had no p16 expression and of these, 67% had HD of p16. SCC of the bladder was also found to have a high frequency of HD of p16 (Gonzalez-Zulueta et al., 1995) . In the light of these results, it would be surprising if ESCC diered drastically from other SCC in having no signi®cant HD of p16.
To explain the discrepant reports concerning HD frequencies of the p16 gene, it was suggested that genetic analyses using homogeneous solution methodologies such as PCR, Northern and Western blotting are very likely to be complicated and rendered ambiguous by the presence of normal cells in a tumor tissue specimen Liggett et al., 1996) . For example, the PCR is especially sensitive and if evidence is sought for HD by looking for the absence of certain sequences in genomic DNA, the amplification of DNA from even a minor percentage of nonneoplastic tissue in the specimen might be interpreted as a positive tumor expression. On this basis, the homogeneity of cultured cells compared to in vivo tumor biopsies readily explains the more frequent documentation of p16 deletions in in vitro systems. We began using quantitative RT-PCR to measure p16 and p16b gene expressions in esophageal tumors in order to determine the quantitative range of these gene expressions in small biopsy specimens of these tumors. We also hoped that it would be possible to detect loss of gene expression, even though it might be expected that using RT-PCR would also encounter problems of false positives caused by the presence of non-neoplastic cells. However, as shown in Tables 1 and 2 , we detected no p16 cDNA in many of the specimens within the limits of sensitivity of our RT-PCR protocol, indicating either that (a) there was little normal tissue content in the specimens, or (b) the p16 expression in that tissue is very low. In fact, these results appear to be due to a combination of both factors. The specimens are examined before analysis to assure that they consist predominantly of tumor tissue but in addition, several previous studies have shown that the expression of p16 is quite low in normal compared to malignant cells. For example, Jen et al. (1994) failed to detect any p16 expression in normal tissues even by RT-PCR. Although we were able to detect p16 expression by RT-PCR in several specimens of normal esophageal tissue, it was on the average about 10-to 30-fold lower than the tumor tissue expressions. Thus, the contribution of any normal cells to the p16 signal from the PCR of tumor specimens is probably quite small, although the apparent p16 expression value for the tumor could be underestimated in the presence of normal cells because their b-actin content would be included in the denominator of the observed p16/b-actin ratio.
Among those tumors that did express p16, the expression varied considerably in all three tumor types. However, the overall variance of the p16 expression values was signi®cantly greater among the ESCC compared to both the EAC or the GAC (P=0.046 and 0.028, respectively, for the dierence in the standard deviations). In the GAC, the variance of p16 expression was similar to that of EAC, but the mean of the expressions was signi®cantly lower than that of EAC or ESCC (P=0.0109). This large variance of p16 expression, especially in the ESCC, is probably indicative of a variety of disruptions in other genes of the G1 checkpoint. The normal regulation of the G1 checkpoint through pRb depends on a proper balance between p16 and cyclin D1 and thus, those tumors with medium expression levels of p16 may have other G1 checkpoint abnormalities, such as inactivated pRb (Shapiro et al., 1995; Ichimura et al., 1996) or commensurately overexpressed cyclin D1 (Dowdy et al., 1993) that could compensate for the presence of p16 and p16b alterations in esophageal tumors K Hayashi et al substantial p16 activity. The low p16 expression in three ESCC and one GAC tumor, near that of the normal tissue, may represent an unbalancing of the cyclin D1/p16 ratio by down-regulation of p16 expression as an alternative to the overexpression of cyclin D1. Sun et al. (1995) suggested that downregulated p16 could be the functional equivalent of deletion. Most studies on p16 aberrations have emphasized loss of expression through methylation or HD or loss of activity through mutation but the role of quantitative dierences in p16 levels in tumorigenesis has been considered relatively little, probably because of the diculty in precisely quantitating mRNA levels and the relationship between speci®c expression levels and tumor suppressor function. Decreased p16 mRNA levels might be caused by natural regulatory mechanisms, or by partial methylation patterns that decrease the rate of transcription but do not eliminate it. However, low observed values could also result from heterogeneous tumor cell populations, in which a subpopulation of cells expresses p16 but the preponderance of tumor cells have no expression. In one ESCC tumor (L24) and one EAC tumor (L3), p16 expression was very high compared to the others. Previous studies have shown p16 overexpression is characteristic of the loss of pRb activity because pRb apparently regulates the expression of p16 (Kratzke et al., 1996; Shapiro et al., 1995) .
The p16b expression values also varied considerably among these tumors but, unlike p16 expression, the variance of p16b expression was not signi®cantly dierent between the ESCC and the adenocarcinomas. In addition, although p16b expression tended to be lower in the GAC than in ESCC or EAC, the dierence in the means was not statistically signi®cant. The p16b/b-actin ratios were consistently higher than the p16/b-actin ratio in all three tumor types. The gene expression values of p16 and p16b in ESCC and EAC are not associated (P=0.9208 and 0.9105, respectively) and thus in these tumors p16 and p16b are regulated independently. In the GAC, however, the association of the p16 and p16b expressions was marginally signi®cant (P=0.0506) but a larger number of tumors need to be analysed before drawing a de®nite conclusion about this relationship.
The restoration of p16b into cells has been shown to have a growth-inhibitory eect (Quelle et al., 1995; Liggett et al., 1996) , indicating that p16b is involved in cell growth regulation but no evidence has as yet been presented that loss of p16b has a speci®c role in tumorigenesis. The fact that we did not ®nd a single case of exclusive deletion of p16b expression could be interpreted to mean that p16 has no appreciable tumor suppressor activity, since loss of p16b expression in itself does not appear to be sucient to promote tumorigenesis. However, the high frequency of HD among the ESCC may also suggest that loss of p16b is a contributing factor for tumorigenesis when it occurs in concert with the loss of p16.
No point mutations were found among the 12 cDNAs that we sequenced, which is contrary to one previous study that reported about a 50% mutation frequency of p16 in esophageal tumors (Mori et al., 1994) but agress with other studies reporting a low mutation frequency of p16 in ESCC (Igaki et al., 1995) and EAC (Zhou et al., 1994) . In contrast to the discrepant data reported for HD frequency, which, as discussed above, are rationalized on the basis of nonneoplastic tissue contamination, we cannot at this time oer any plausible explanation for dierences in mutation frequency reported in these studies. There may be technical reasons, or it is possible that the dierences in reported mutation frequencies are real and are a result of the patients of each study being derived from dierent geographical areas and thus being exposed to dierent carcinogens.
The high frequency of deleted p16 genes in ESCC and the comparative rarity of this event in adenocarcinomas are probably a re¯ection of their distinct pathways of tumorigenesis. ESCC and EAC have dierent spectra of p53 mutations (Galiana et al., 1995) , with that of ESCC being more typical of exogenous carcinogens and that of EAC with endogenous mutagenesis (Huang et al., 1993) . This dierence in p53 mutation patterns is consistent with what is known about the etiology of the tumors: ESCC are thought to be caused primarily by exposure of the tissue to carcinogens such as tobacco smoke, alcohol, and pickled vegetables whereas the causes of EAC are not as clear but appear to be associated with high fat ± low ®ber diets (Attwood et al., 1992) and esophageal re¯ux (Brown et al., 1995) . EAC is of considerable interest at present because its incidence is increasing at a rate exceeding that of any other cancer for reasons that are not yet understood (Blot et al., 1991 Ilson et al., 1995) . Substantial molecular distinctions have also been noted between non-small cell lung squamous cell carcinoma and adenocarcinoma in terms of dierent LOH frequency on various chromosomes (Tsuchiya et al., 1992) . These carcinomas dier etiologically and interestingly, the incidence of non small-cell lung adenocarcinoma has also been increasing in recent years in the United States (Wyner and Homan, 1994) just as EAC has. The similarity of the gene expression patterns in EAC and GAC is consistent with the idea that these tumors are closely related and arise by similar tumorigenic mechanisms.
The type of DNA alterations occurring in the tumor may have clinical signi®cance. The region of HD has been shown to span as much as 1 Mb (GonzalezZulueta, 1995) (although the deletion can also be very small as in tumor L241 of this study). Thus, the occurrence of HD targeted at p16 may also cause codeletion of other tumor suppressor genes, such as the p15 gene located near the p16 locus on chromosome 9 (Stone et al., 1995b) . On the other hand, methylation can in principle be gene-speci®c and in fact has been shown to selectively inactivate either the p16 or the p15 gene leaving the other one functional (Herman et al., 1996) . It is of interest to note that, although ESCC appear to have a much higher response rate to some chemotherapy protocols than do EAC (Ilson et al., 1995) , patients with EAC have been reported in some studies to have a better survival prognosis than ESCC patients treated with the same regimens (Vigneswaran et al., 1993) . The association of the type of p16 alteration found in these tumors with recurrence and patients' survival will be reported when the data become available. Historically, clinical treatment of esophageal cancer has not distinguished between AC and SCC, but as more molecular dierences between p16 and p16b alterations in esophageal tumors K Hayashi et al them are discovered, it may be possible to devise more eective clinical strategies speci®c to each tumor type.
Materials and methods
Tumor material
Endoscopic biopsies of esophageal and gastric tumors prior to treatment were obtained from patients entered on protocols at the University of Southern California/Los Angeles County Medical Center, Los Angeles, CA; Memorial Sloan-Kettering Cancer Center, New York, NY; Women's Medical College, Tokyo, Japan; Department of Surgery, Technical University, Munich, Germany. All biopsy specimens were snap frozen in liquid nitrogen and shipped in dry ice to the USC/Norris Cancer Center. Each tumor specimen was evaluated histopathologically for tumor content and all those submitted for analysis contained 480% tumor cells.
RT-PCR quantitation of relative mRNA content
The procedure for quantitation of gene expression used in this study has been described previously (Horikoshi et al., 1992; Lenz et al., 1995) . In brief, the method involves preparation of cDNA from RNA isolated from each tumor using reverse transcriptase and random hexamers, and PCR ampli®cation of the speci®c cDNA of interest in the range of concentrations that gives rise to a linear curve of the corresponding PCR products. An internal standard gene from the same cDNA solution is ampli®ed separately. If the reference gene is expressed at similar levels in all cells, the amount of its PCR product should represent the amount of RNA isolated from the specimen. Use of a reference gene as a denominator avoids the need to directly quantitate the RNA, which could be a major source of error for analysis of small tissue specimens. We found previously that with b-actin as the reference gene, a good linearity is obtained between gene expression values determined by RT-PCR and protein content determined by immunohistochemistry (Johnston et al., 1995) . Once the concentration ranges for linear ampli®cation are established for the cDNA of the target gene and the reference gene, the ratio of the slopes generates an empirical number proportional to the amount of mRNA of interest in the tissue normalized to total RNA. Because the ratios of gene expressions should remain constant regardless of the absolute yield of RNA, this relative expression approach is well suited for quantitating relative mRNA in small tissue specimens from which reproducible isolation of good quality RNA can sometimes be problematical. This method has been used by us (Lenz et al., 1996; Johnston et al., 1996) as well as by others (Kuo et al., 1996) to quantitate various gene expressions in tumor biopsy specimens.
RT-PCR quantitation of p16 and p16b expression
Isolation of RNA from tumors and synthesis of cDNA using random hexamers was carried out as previously described . The PCR primers for selective ampli®cation of p16 and p16b cDNA were similar but not identical to those described in an earlier study (Stone et al., 1995) , and in addition a T7 polymerase promoter sequence ('T7'=TAATAGGACTCACTATAGGGA) was appended to the 5' primer so that the PCR products could subsequently be converted to cRNA. This last step was designed to further increase the sensitivity of the RT-PCR for quantitation of non-abundant mRNA. The sequence of the p16-speci®c primer was 5'-'T7'-AACGCACCGAA-TAGTTACG; that of the p16b-speci®c primer was 5'-'T7'-TACTGAGGAGCCAGCTCTA and that of the common 3' primer was 5'-AGCACCACCAGCGTGTC. To prevent ampli®cation of genomic DNA, these primers are designed to bind to the exon 1-exon 2 junctions for both genes. The sequences of the b-actin primers were 5'-'T7'-AGAGCGGGAAATCGTGCGTGACATT and 5'-GATGGAGTTGAAGGTA. PCR reactions were made up as described previously PCR ampli®cation of genomic DNA DNA was isolated from the interphase and phenol phase separated from the initial homogenate during RNA isolation as described (Chomczynski, 1993) . In some cases, because RNA isolations are usually contaminated with considerable genomic DNA (Larrick and Siebert, 1995), we were able to use the cDNA solutions for PCR of DNA. For selective PCR ampli®cation of genomic DNA, one or both of the primers were designed to bind to intron sequences. The p16 primer sequences were 5'-T7'-AGAGGGGGAGAGCAGGCA and 5'-AAGCGCTACC-TGATTCCAATT. The b-actin primers were 5'-'T7'-AGAGCGGGAAATCGTGCGTGGTGACATT and 5'-AGACAGTCTCCACTCACC. The PCR cycling conditions were the same as above for cDNA ampli®cation.
RT-PCR sequencing of the p16 gene
To sequence p16 cDNA, 2 overlapping fragments were prepared. Fragment A covering exon 1 and about half of exon 2 was obtained using primers 156 (TAATACGACT-CACTATAGGGAAACGCACCGAATAGTTACGGTCG) and 148 (GCAGCACCACCAGCGTG). Fragment B covering exon 2 and exon 3 was obtained with primers 174 (ACTCTCACCCGACCCGTGCAC) and 112 (TAA-TACGACTCACTATAGGGAGTAGGACCTTCGGTGA-CTGATG). One microliter of each cDNA solution was used for each PCR reaction, and the PCR conditions were identical to those used in quantitation except that the cycle number was increased to 35 in order to increase the yields of the fragments. The primers were separated from the PCR products by Centricon ®ltration according to the manufacturer's instructions (Amicon Co.). Each product was sequenced using the Amplicycle sequencing kit (Perkin-Elmer Co.). Primers were end-labeled with [g-32 P] ATP and T4 kinase according to the manufacturer's instructions and cycle sequencing was carried out for 20 cycles of 968C (15 s), 658C (30 s) and 728C (30 s). Fragment A was sequenced bidirectionally with primers 173 (AACGCACCGAATAGTTACGGTCG) and 148 and fragment B with primers 181 (CATCTATGCGGG-CATGGTTAC) and 149 (TGGACGTGCGCGATGC).
